Clinicopathological significance of DEK overexpression in serous ovarian tumors

Pathology International

Volumn 59, Issue 7, 2009, Pages 443-447

  Han, Songying ^a   Xuan, Yanhua ^a   Liu, Shuangping ^a   Zhang, Meihua ^a   Jin, Dongzhu ^b   Jin, Renshun ^a   Lin, Zhenhua ^a,b,c  

^a Department of Pathology ^*  (China)

^b YANBIAN UNIVERSITY   (China)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DEK; Immunohistochemistry; Ovarian serous tumors

Indexed keywords

DEK PROTEIN; PHOSPHOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER STAGING; CANCER THERAPY; CYSTADENOCARCINOMA; CYSTADENOMA; DRUG TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY ADENOCARCINOMA; OVARY CANCER; OVARY TUMOR; PAPILLOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

AGED, 80 AND OVER; CHROMOSOMAL PROTEINS, NON-HISTONE; CYSTADENOCARCINOMA, SEROUS; CYSTADENOMA, SEROUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 67650838426     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2009.02392.x     Document Type: Article

References (20)

1. Serrano-Olvera A, Duenas-Gonzalez A, Gallardo-Rincon D, Candelaria M, De La garza-Salazar J. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 2006 32 : 180 90.
2. Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, Shih IEM. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 2005 65 : 1994 2000. (Pubitemid 40478629)
3. Mor-Vaknin N, Punturieri A, Sitwala K et al. The DEK nuclear autoantigen is a secreted chemotactic factor. Mol Cell Biol 2006 26 : 9484 96.
4. Casas S, Nagy B, Elonen E et al. Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia. Leuk Lymphoma 2003 44 : 1935 41.
5. Kondoh N, Wakatsuki T, Ryo A et al. Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res 1999 59 : 4990 96.
6. Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC, Nakamura Y. Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 2002 21 : 4120 28.
7. Wise-Draper TM, Allen HV, Thobe MN et al. The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. J Virol 2005 79 : 14 309 17.
8. Wu Q, Li Z, Lin H, Han L, Liu S, Lin Z. DEK overexpression in uterine cervical cancers. Pathol Int 2008 58 : 378 82.
9. Tavassoli FA, Devilee P. Tumours of the ovary and peritoneum. In : Tavassoli FA, Devilee P, eds. Pathology and Genetics-Tumours of the Breast and Female Genital Organs. New York : International Agency for Research on Cancer, 2003 113 97.
10. Silverberg SG. Histopathologic grading of ovarian carcinoma: A review and proposal. Int J Gynecol Pathol 2000 19 : 7 15. (Pubitemid 30010638)
11. AJCC. AJCC Cancer Staging Manual, 6th edn. New York : Springer Verlag, 2002.
12. Lin Z, Liu M, Li Z, Kim C, Lee E, Kim I. DeltaNp63 protein expression in uterine cervical and endometrial cancers. J Cancer Res Clin Oncol 2006 132 : 811 16.
13. Vartiainen J, Lassus H, Lehtovirtal P et al. Combination of serum hCGb and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma. Int J Cancer 2008 122 : 2125 29.
14. Kappes F, Fahrer J, Khodadoust MS et al. DEK is a poly (ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. Mol Cell Bio 2008 28 : 3245 57.
15. Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H, Wells SI. Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol 2006 26 : 7506 19.
16. Carro MS, Spiga FM, Quarto M et al. DEK expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle 2006 5 : 1202 7.
17. Clearly J, Sitwala KV, Khodadoust MS et al. P300/CBP-associated factor drives DEK into interchromatin granule clusters. J Biol Chem 2005 280 : 31 760 67.
18. Kappes F, Damon C, Knippers R, Przybulski M, Pinna LA, Gruss C. Phosphorylation by protein kinase CK2 changes the DNA binding properties of the human chromatin protein DEK. Mol Cell Biol 2004 24 : 6011 20.
19. Waldmann T, Eckerich C, Baack M, Gruss C. The ubiquitous chromatin protein DEK alters the structure of DNA by introducing positive supercoils. J Biol Chem 2002 277 : 24 988 94.
20. Wise-Draper TM, Morreale RJ, Morris TA et al. DEK proto-oncogene expression interferes with the normal epithelial differentiation program. Am J Pathol 2009 174 : 71 81.